TELA Bio, Inc.

TELA

$0.82

+4.99%

N/A+$0.04

Healthcare

Medical - Devices

NASDAQ

Active Trading

TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation ...

CEO Profile of TELA

Antony Koblish

TELA Bio, Inc.

Tenure 14yKey-man risk: Medium

Antony Koblish is a visionary med-tech founder who has successfully built TELA Bio from a startup to a significant player in the hernia repair market. While his strength in innovation...

Key Risk

•Dependency on capital markets for funding operational burn.

•High execution risk in reaching profitability goals.

Key Tailwind

•Strong clinical positioning of OviTex products.

•New, experienced management team and refreshed board oversight.

•Continued market shift toward biologic alternatives.

Antony Koblish

TELA Bio, Inc. (TELA) · NASDAQ

AmericanTenure 14 yearsFounder CEOKey-man risk: Medium

University of Pennsylvania (Engineering)

antony-koblish-28515643

Origin Story

A seasoned medical device entrepreneur who leveraged his success at Orthovita to co-found TELA Bio, focusing on innovative soft-tissue reconstruction.

Early Life: Formative experiences in mechanical engineering and early-stage medical device commercialization.

First Break: President and CEO of Orthovita, Inc., leading it through growth to a $316 million acquisition by Stryker in 2011.

Path to CEO: After the successful exit of Orthovita, Koblish co-founded TELA Bio in 2012 with a vision to shift the hernia repair and soft-tissue reconstruction market away from traditional synthetic meshes toward more biologic-friendly solutions.

Original Vision: To optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy in surgical reconstruction.

Antony Koblish is a veteran med-tech entrepreneur with over 25 years of experience. After steering Orthovita through its successful development and subsequent exit to Stryker, he applied that deep industry expertise to identify an unmet clinical need in hernia repair. He founded TELA Bio in 2012 to commercialize OviTex and other reconstructive products, building the company from a startup to a public entity listed on the NASDAQ, navigating the complexities of scaling a med-tech company through various capital raises and commercial launches.

med-tech entrepreneurserial foundersurgical innovation

Investment Take

Antony Koblish is a visionary med-tech founder who has successfully built TELA Bio from a startup to a significant player in the hernia repair market. While his strength in innovation...

Key Tailwinds

Strong clinical positioning of OviTex products.

New, experienced management team and refreshed board oversight.

Continued market shift toward biologic alternatives.

Key Risks

Dependency on capital markets for funding operational burn.

High execution risk in reaching profitability goals.

Market volatility and intense competition in the hernia mesh category.

Career History

An experienced executive career primarily focused on scaling biosurgical and orthobiologics companies.

TELA Bio

Initiative: Co-Founder, President & CEO

Period: 2012–Present

Event: Took company public, led multi-product commercial expansion, scaled organization to over 200 employees.

Outcome: Recent growth targets missed, currently navigating a strategic pivot and board refreshment.

Orthovita

Initiative: President & CEO

Period: Prior to 2011

Event: Grew valuation to a $316M exit sale to Stryker.

1315 Capital

Initiative: Operating Partner

Period: 2014–2025

Event: Provided strategic oversight for healthcare investments.

executive leadershiphealthcare industrycommercialization

Company Performance

Experiencing significant growth challenges and stock price pressure, leading to a recent management and board shakeup.

Revenue: Growth remains positive but moderated; 2026 guidance was cut to 8% in early 2026.

Profitability: Currently loss-making; focused on a 'path to profitability'.

Stock: Significant decline in market value; trading at historical lows (near $0.85–$0.90 in mid-2026) compared to past peaks.

•Successfully navigated company through IPO.

•Launched OviTex product line in the US market.

•Recent earnings misses (Q1 2026).

•Significant stock price depreciation over the last 18 months.

growth challengesstrategic pivotturnaround attempt

Management Ability

A hands-on, deeply experienced operator currently facing execution hurdles in a changing market.

Style: Operator-led, highly experienced in medical technology sales.

Koblish is a deeply ingrained leader within the TELA Bio ecosystem, having served as CEO since its inception. He is praised for his industry knowledge and ability to navigate complex medical device regulatory and commercial environments. However, recent performance issues have triggered a strategic board refreshment and an expansion of the executive leadership team to better navigate the current phase of commercial growth.

med-tech expertisestrategic realignment

Capital Allocation

Historically focused on high-growth commercial expansion, now pivotally shifting toward capital discipline and profitability.

Requires consistent dilution and public market raises to fund ongoing growth and operational burn.

IPO (TELA): Provided capital for commercial expansion.

As a co-founder, Koblish has managed multiple funding rounds, including public equity raises to fuel the company's commercial engine. With the current market pressure and growth moderation, his allocation strategy is moving toward a more disciplined focus on 'path to profitability' to improve margins and reduce operational burn.

capital intensivedilutionefficiency

Fundraising & Financing

Frequent user of public equity markets to fuel operations and commercial scaling.

Public offering · $45M (2023): Capital injection, but triggered share price reaction.

Dilution: Significant; frequent reliance on equity raises for ongoing growth and operational coverage.

Koblish has demonstrated a successful track record in fundraising from VCs and subsequently from public equity markets. His financing philosophy is heavily reliant on supporting commercial scaling, which has led to noticeable dilution for long-term shareholders as the company strives for profitable growth.

capital raiserfrequent dilution

Governance & Control

Founder-led governance currently undergoing significant external oversight and refreshment.

Dual-class Shares: No

Share Class Detail: Single class of common stock typical for this market tier.

As a co-founder, Koblish has historically enjoyed significant board support, but as of April 2026, the company initiated a strategic board refreshment, adding four new directors to strengthen governance and accelerate the path to profitability, signaling a shift toward more external oversight.

founder governanceboard refreshment

Health & Succession

No public concerns; succession planning increasingly managed by the board.

Health Status: No public concerns.

Succession Plan Disclosed: No

Key-man Risk: Medium

As co-founder/CEO, there is inherent key-man risk, though recent management expansion reduces this dependency.

key-man riskno concerns

R&D & Tech Vision

Maintains a strong innovation pipeline focused on soft-tissue repair materials.

Sustained investment as a core component of the business model.

OviTex product line: Succeeded; core revenue driver for the company.

High; effectively transitioned from early-stage concept to established commercial products.

•Identifying the shift away from synthetic hernia mesh early in the company's formation.

Koblish's vision is rooted in his technical background, consistently pushing for product innovation that addresses clinical failures in legacy mesh products. He has overseen the successful launch and development of the OviTex portfolio, which remains a key differentiator.

innovation drivenlong-term vision

Talent Recruitment

Strong ability to attract industry talent, recently supplementing the team with high-experience commercial leaders.

Jeffrey Blizard (President): Brought deep industry experience to accelerate growth.

Strong, though currently being reshaped to meet new operational challenges.

Retention: Strong; has maintained a stable, experienced core leadership team since the IPO.

Koblish has built a team characterized by deep med-tech expertise. The recent hire of Jeffrey Blizard as President and the addition of four new board members highlights a talent strategy that prioritize commercial scaling and experienced management oversight.

talent magnetexperienced leadership

Strengths

Demonstrated ability to identify clinical market gaps and drive initial product commercialization.

Strategic Vision: Successfully identified the market need for biologic-friendly reconstruction materials before widespread adoption.

Capital Access: Proven ability to secure funding from public and private investors over many years.

industry knowledgevisionary

Weaknesses & Failures

Struggles with scaling profitability and managing market expectations during late-stage commercial growth.

Operational Scaling

Difficulty achieving profitability metrics while maintaining the growth rates expected by the market.

Example: 2026 guidance cuts and recent earnings misses.

scaling hurdlesexecution risk

Marketing & Brand

Focused on repositioning hernia repair and soft-tissue reconstruction away from legacy synthetic materials.

Positioned as the innovative, biologic-friendly alternative in a commoditized hernia mesh market.

The marketing strategy emphasizes clinical outcomes and long-term patient health compared to traditional synthetic meshes. Koblish personally leads the branding vision, consistently highlighting the technology's clinical advantage during investor and public engagements.

market disruptionbrand repositioning

PR & Communication

Transparent and active, maintaining a high profile as the face of the company.

Media Reputation: Positive industry standing, though current financial underperformance has increased critical scrutiny.

Event: Stock price depreciation/Earnings miss

Handling: Engaged in strategic board refreshment and leadership expansion to address investor concerns.

Koblish is highly articulate on earnings calls and industry conferences, consistently framing the long-term potential of TELA Bio. He has been proactive in communicating strategic changes and board refreshment plans to stabilize investor sentiment during recent headwinds.

transparent communicationproactive management

Supply Chain of TELA

Upstream / Downstream / Proxies

Upstream

Aroa Biosurgery LtdASX:ARXNew Zealand Sheep Farming Industry (supplier to Aroa)Medical Polymer/Suture Manufacturers (unidentified suppliers to Aroa)

Downstream

Aroa Biosurgery LtdASX:ARXHealthTrust Purchasing Group (HCA Healthcare affiliate)Sana GmbH (Germany)GD Medical (Netherlands)Vizient Inc.Premier Inc.NASDAQ:PINC MiMedx Group, Inc.NASDAQ:MDXGNext Science LtdASX:NXSUS Hospitals & Integrated Delivery Networks (IDNs)European Hospitals & Clinics

Proxies

Aroa Biosurgery LtdASX:ARXMiMedx Group, Inc.NASDAQ:MDXG Becton Dickinson and CompanyNYSE:BDX Organogenesis Holdings Inc.NASDAQ:ORGO

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer